Program
dersimelagon
Also written as “MT-7117”, “Dersimelagon” and “MT-7117 low dose”.
Its studies are mostly in Protoporphyria, Erythropoietic · Scleroderma, Diffuse · Lymphoma, Follicular · Renal Insufficiency, led by Tanabe Pharma.
Furthest: phase 3, since May 20, 202013 company-led studies, 1 open or runningNext primary completion: Dec 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Tanabe Pharma | 131 open or running | phase 3since May 20, 2020 | Jul 6, 2016 | Dec 2027phase 3 · NCT05005975 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 6, 2016First study: phase 1 study in HealthyFirst studyNCT02834442 · 144 enrolled · United Kingdom
- Mar 18, 2018Phase 1 study in Healthy VolunteerNCT03503266 · 6 enrolled · United Kingdom
- Apr 23, 2018Phase 2 study in Protoporphyria, ErythropoieticNCT03520036 · 102 enrolled · United States
- Sep 18, 2018Phase 1 study in Healthy VolunteerNCT03688022 · 50 enrolled · Germany
- Oct 3, 2019Phase 1 study in Lymphoma, FollicularNCT04116476 · 23 enrolled · United States
- May 20, 2020Phase 3 study in EPPNCT04402489 · 184 enrolled · United States, Australia, Canada and more
- Jun 17, 2020Phase 2 study in Scleroderma, DiffuseNCT04440592 · 76 enrolled · United States, Belgium, Canada and more
- Nov 23, 2020Phase 1 study in Renal InsufficiencyNCT04656795 · 32 enrolled · Germany
- Mar 10, 2021Phase 1 study in Healthy SubjectsNCT04793295 · 112 enrolled · United States
- Jul 28, 2021Phase 3 study in EPPNCT05005975 · 286 enrolled · United States, Australia, Bulgaria and more
- Jan 6, 2022Phase 1 study in Healthy SubjectsNCT05241535 · 29 enrolled · United States
- Nov 17, 2023Phase 3 study in Protoporphyria, ErythropoieticNCT06144840 · 165 enrolled · United States, Australia, Bulgaria and more
- Apr 24, 2025Phase 1 study in Healthy SubjectsNCT06994286 · 40 enrolled · China
Ahead
- Dec 2027Primary completion: phase 3 study in EPPNCT05005975
TargetBeta
MC1R →read by rule
“An orally bioavailable selective, non-peptide melanocortin-1 receptor (MC1R; melanocyte-stimulating hormone receptor; MSHR; melanin-activating peptide receptor; melanotropin receptor) agonist, that can potentially be used to prevent phototoxicity”NCIt, by rule
“Melanocortin receptor 1 agonist”ChEMBL 37, by rule
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06994286Healthy Subjects · China | 1 | Completed | Jul 21, 2025 | 40 |
| NCT06144840Protoporphyria, Erythropoietic · United States, Australia, Bulgaria and more | 3 | Completed | Apr 14, 2026 | 165 |
| NCT05241535Healthy Subjects · United States | 1 | Completed | Feb 23, 2022 | 29 |
| NCT05005975EPP · United States, Australia, Bulgaria and more | 3 | Active, not recruiting | Dec 2027 | 286 |
| NCT04793295Healthy Subjects · United States | 1 | Completed | Feb 4, 2022 | 112 |
| NCT04656795Renal Insufficiency · Germany | 1 | Completed | Dec 4, 2021 | 32 |
| NCT04440592Scleroderma, Diffuse · United States, Belgium, Canada and more | 2 | Completed | Jan 17, 2024 | 76 |
| NCT04402489EPP · United States, Australia, Canada and more | 3 | Completed | Dec 14, 2021 | 184 |
| NCT04116476Lymphoma, Follicular · United States | 1 | Completed | Feb 16, 2021 | 23 |
| NCT03688022Healthy Volunteer · Germany | 1 | Completed | Dec 22, 2018 | 50 |
| NCT03520036Protoporphyria, Erythropoietic · United States | 2 | Completed | Sep 28, 2019 | 102 |
| NCT03503266Healthy Volunteer · United Kingdom | 1 | Completed | May 11, 2018 | 6 |
| NCT02834442Healthy · United Kingdom | 1 | Completed | Jun 2017 | 144 |
How it is read
Names in the registry
- “MT-7117”, 9 entries
- “Dersimelagon”, 1 entry
- “MT-7117 low dose”, 1 entry
- “MT-7117 high dose”, 1 entry
- “MT-7117 Low Dose”, 1 entry
Conditions, from the studies’ own filings
- Protoporphyria, Erythropoietic, 2 studies
- Scleroderma, Diffuse, 1 study
- Lymphoma, Follicular, 1 study
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.